Back to top

RSV

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.

...

 

 

 

 

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Advice on staying health during cold, flu and COVID season

January can be the worst month for these illnesses. With vaccination rates low, what can you do to protect yourself from respiratory viruses, including influenza, COVID-19 and RSV?

...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to RSV